Quarterly report pursuant to Section 13 or 15(d)

Development Award and Deferred Revenue (Details Narrative)

v3.8.0.1
Development Award and Deferred Revenue (Details Narrative)
1 Months Ended 3 Months Ended
Jan. 26, 2018
USD ($)
$ / shares
shares
Jan. 31, 2017
USD ($)
Aug. 31, 2016
USD ($)
Apr. 20, 2015
USD ($)
Installments
Apr. 20, 2015
USD ($)
Installments
Nov. 30, 2017
USD ($)
Nov. 30, 2015
USD ($)
May 31, 2015
USD ($)
Mar. 31, 2018
USD ($)
$ / shares
shares
Mar. 31, 2017
USD ($)
Development Award [Line Items]                    
Amount received upon achievement                 $ 6,250,000  
Revenue                 $ 950,442 $ 1,293,697
Warrant to purchase of common stock | shares                 2,288,500  
Warrant exercisable price per sahre | $ / shares                 $ 6.33  
Reclassified to contract asset and classified in prepaid expenses                 $ 915,667  
Additional paid in capital, fair value of warrant issued                 6,215,225  
Phase 2b Clinical Trial [Member]                    
Development Award [Line Items]                    
Amount received upon achievement $ 6,250,000                  
Cystic Fibrosis Foundation warrants [Member]                    
Development Award [Line Items]                    
Revenue                 $ 18,784,775  
Warrant to purchase of common stock | shares 1,000,000               1,000,000  
Warrant exercisable price per sahre | $ / shares $ 13.20               $ 13.20  
Warrant exercisable shares of common stock | shares 500,000               500,000  
Warrant expires date Jan. 26, 2025                  
Additional paid in capital, fair value of warrant issued                 $ 6,215,225  
2015 CFFT Award Agreement [Member]                    
Development Award [Line Items]                    
Amount received upon achievement   $ 1,000,000 $ 1,000,000     $ 500,000 $ 1,250,000 $ 1,250,000    
Revenue                 $ 1,293,697
2015 CFFT Award Agreement [Member] | Oral Anti-inflammatory Drug [Member]                    
Development Award [Line Items]                    
Amount received upon achievement         $ 5,000,000          
2015 CFFT Award Agreement [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                    
Development Award [Line Items]                    
Payment due period after the first commercial sale       90 days            
Number of installments | Installments       3 3          
Royalty payment, sales target       $ 500,000,000 $ 500,000,000          
2015 CFFT Award Agreement [Member] | Maximum [Member]                    
Development Award [Line Items]                    
Development award received       5,000,000 $ 5,000,000          
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Commercialization of the Product [Member]                    
Development Award [Line Items]                    
Royalty payable       25,000,000            
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                    
Development Award [Line Items]                    
Royalty payable       5,000,000            
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Transfer Sale or Licensing [Member]                    
Development Award [Line Items]                    
Royalty payable       $ 15,000,000            
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                    
Development Award [Line Items]                    
Development award received $ 25,000,000                  
Investment Agreement [Member]                    
Development Award [Line Items]                    
Revenue                 950,442  
Reclassified to contract asset and classified in prepaid expenses                 $ 25,000,000  
Investment Agreement [Member] | Cystic Fibrosis Foundation warrants [Member]                    
Development Award [Line Items]                    
Warrant exercisable shares of common stock | shares 500,000               500,000  
Warrant expires date                 Jan. 26, 2025  
Investment Agreement [Member] | May 2018 [Member] | Phase 2b Clinical Trial [Member]                    
Development Award [Line Items]                    
Amount received upon achievement $ 6,250,000